Drug Profile
Tirvalimogene teraplasmid - Genexine
Alternative Names: GX-188; GX-188E; NOV-1702; Papitrol; Papitrol-188; pGX27-E6E7Latest Information Update: 05 Jul 2023
Price :
$50
*
At a glance
- Originator Genexine
- Developer Genexine; Merck & Co; Yonsei University
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cervical intraepithelial neoplasia; Head and neck cancer
Most Recent Events
- 02 Jun 2023 Updated pharmacodynamics data from a phase II trial in Head and neck cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 26 May 2023 Efficacy and pharmacodynamics data from a phase II trial in Head and neck cancer released by Genexine
- 20 Jan 2023 Genexine completes a phase I/II trial in Cervical cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in South Korea(IM) (NCT03444376)